Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 49 of 58, showing 10 Applications out of 576 total, starting on record 481, ending on 490

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

481.

ECCT/14/09/01   Extension to study MALARIA-055 PRI (110021) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’candidate malaria vaccine (SB257049) in infants and children in Africa
    An open extension to the phase III, multi-center study MALARIA-055 PRI (110021) to evaluate long-term efficacy, safety and immunogenicity of the RTS,S/AS01E candidate vaccine against malaria disease caused by Plasmodium falciparum in infants and children in Africa.   Study number: MALARIA-076 (200599)   
Principal Investigator(s)
1. Walter Otieno
Site(s) in Kenya
Kenya Medical Research Institute/Walter Reed Project
 
23-09-2015 View

482.

ECCT/15/06/01  
    Pyronaridine-artesunate and artemether-lumefantrine for the treatment of paediatric uncomplicated falciparum malaria in Western Kenya   
Principal Investigator(s)
1. Patrick Sawa
Site(s) in Kenya
St. Judes Clinic, ICIPE
 
04-09-2015 View

483.

ECCT/14/09/03   Breast Feeding Study
    An open-label, short-duration, repeat-dose study of breast milk excretion and infant absorption of daily oral Tenofovir Disoproxil Fumarate/Emtricitabine when used by HIV-1 uninfected lactating women    
Principal Investigator(s)
1. Jared Murray Baeten
2. Nelly Rwamba Mugo
Site(s) in Kenya
Partners in Prevention, Thika Site
 
19-08-2015 View

484.

ECCT/14/08/03   STAND Study (Shortening Treatment by Advancing Novel Drugs)
    Long Title:   A Phase 3 Open Label Partially Randomised Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA-824 plus Pyrazinamide after 4 and 6 months of Treatment in Adult Subjects with Drug Sensitive Smear Positive Pulmonary Tuberculosis and after 6 months of Treatment in Adult Subjects with Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis       Short Title:   STAND Study (Shortening Treatment by Advancing Novel Drugs)   
Principal Investigator(s)
1. Dr Videlis Nduba
2. Dr Evans Amukoye
Site(s) in Kenya
1. KEMRI-CRDR(East Nairobi) (Nairobi City county)
2. KEMRI-CRDR(West Nairobi) (Nairobi City county)
 
17-08-2015 View

485.

ECCT/15/06/02   ZINC in Sickle cell study
    The effects of Zinc supplementation in children with sickle cell disease in Western Kenya: a pilot study.   
Principal Investigator(s)
1. Lucas Otieno Tina
Site(s) in Kenya
Health Facilities in Western Kenya
 
17-08-2015 View

486.

ECCT/15/06/03   DolutegrAvir With NRTIs as second-line treatment (DAWNING)
    A Phase 3b, randomised, open-label study of the antiviral activity and safety of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy   
Principal Investigator(s)
1. Dr. Evans Inyangala Amukoye
2. Dr. Maricianah Atieno Onono
Site(s) in Kenya
1. Center for Respiratory Diseases Research, CRDR, KEMRI, Nairobi (Nairobi City county)
2. KEMRI-Research Care and Training Program (RCTP), Family AIDS Care and Education Services (FACES), Lumumba health centre (Kisumu county)
 
29-07-2015 View

487.

ECCT/15/03/01   A phase III, non-inferiority trial using Carbetocin room temperature stable (RTS) for the prevention of postpartum haemorrhage during the third stage of labour in women delivering
    A phase III, randomized, double-blind, active, controlled, multinational, multicentre,  non-inferiority trial using Carbetocin room temperature stable (RTS) for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally.   
Principal Investigator(s)
1. Zahida Qureshi
Site(s) in Kenya
Kenyatta National Hospital
 
27-07-2015 View

488.

ECCT/15/06/04   A5316
        A5316           Evaluating Pharmacokinetic Interactions with Vaginal Ring Contraceptives and Antiretroviral Therapy   
Principal Investigator(s)
1. Dr. Esther Mumbi Makanga Makanga
2. Dr. Victor Akelo Akelo
3. Dr.Victor O. Mudhune Mudhune
4. Dr. Kevin P. Cain Cain
Site(s) in Kenya
KEMRI- CDC
 
17-07-2015 View

489.

ECCT/15/04/02  
    Plasma concentration profiles after oral  administration of oleylphosphocholine tablet  formulation: safety, tolerability and pharmacokinetics  of 100 mg single dose in healthy male volunteers.   
Principal Investigator(s)
1. Ravasco Rashid Juma
Site(s) in Kenya
KEMRI
 
15-06-2015 View

490.

ECCT/15/01/03   Simplifying ShangRing Circumcision for Men and Boys
    Simplifying the Shang Ring Technique for Circumcision of Men and Boys   
Principal Investigator(s)
1. Mark Barone
Site(s) in Kenya
1. Homa Bay Level IV hospital (Homa Bay county)
2. Vipingo Health Centre (Kilifi county)
 
15-04-2015 View